Who founded Stylus Medicine?

Stylus Medicine was founded by Michael C. Bassik, Ph.D..

Who are Stylus Medicine's investors?

Stylus Medicine's investors include Brainstorm Ventures, CAL Innovation, California Innovation Fund, Khosla Ventures, Neva Sgr., RA Capital, Tachyon Ventures, AbbVie.

Stylus Medicine

8 known investors

Find your way into Stylus Medicine

Paths you didn't know you had: your email and LinkedIn already hold routes to the Stylus Medicine team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Stylus Medicine develops in vivo genetic medicines using engineered recombinases, with initial focus on creating CAR-T therapies delivered via lipid nanoparticles for oncology, autoimmune, and genetic diseases.

Biotech Digital Health Medical Devices

Founders & leadership

Michael C. Bassik, Ph.D.Scientific FounderMichael Bassik is a founder of Stylus Medicine, which develops in vivo genetic medicines using engineered recombinases. He holds a Ph.D. and has background in genetic engineering and therapeutic development.

Emile Nuwaysir, Ph.D.Chairman & Chief Executive OfficerEmile Nuwaysir holds a Ph.D. and has founded or led multiple biotechnology startups developing engineered cellular medicines, multispecific antibodies, and genomics platforms. He is Chairman and CEO of Stylus Medicine, which develops in vivo genetic medicines using engineered recombinases for CAR-T therapies and other indications.

Jason Fontenot, Ph.D.Chief Scientific Officer

Ami BhattFounder

Lacramioara BintuFounder

Michael BassikFounder

Patrick D HsuFounder

Investors · 8

Brainstorm Ventureslisted by Brainstorm VenturesSan Francisco

How we know: Brainstorm Ventures's portfolio page · Not right? Tell us

CAL Innovationlisted by CAL InnovationMill Valley

California Innovation Fundlisted by California Innovation FundBerkeley

How we know: California Innovation Fund's portfolio page · Not right? Tell us

Khosla Ventureslisted by Khosla VenturesMenlo Park · $100K – $20M

How we know: Khosla Ventures's portfolio page · funding news · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Neva Sgr.listed by Neva Sgr.Turin

How we know: the VCSheet dataset · Not right? Tell us

RA Capitallisted by RA CapitalBoston

How we know: RA Capital's portfolio page · funding news · Not right? Tell us

Tachyon Ventureslisted by Tachyon VenturesLos Angeles

AbbViereportedCambridge · $300K – $3M

How we know: a partner's Signal profile · Not right? Tell us

Founder mafia

3 people who came through Stylus Medicine went on to found or lead other companies.

Josh ResnickCo-Founder & Board MemberFounded Synolo Therapeutics +4 Nessan BerminghamInvestor & Board MemberFounded Korro Bio +2 Emile Nuwaysir, Ph.D.Chairman & Chief Executive OfficerFounded Invenra +1

Related companies · 5

Talus BioTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.

TrisaluslifesciTriSalus develops a therapeutic platform combining its Pressure-Enabled Drug Delivery (PEDD) method with immune-activating therapies to overcome intratumoral pressure and immunosuppression that limit treatment of liver and pancreatic tumors. The platform is designed to be used alongside systemic immunotherapies such as checkpoint inhibitors for cancer patients.

LatusLatus develops gene therapy research and development capabilities leveraging cell and gene therapy expertise. The company operates from Philadelphia and Boston, serving the biotechnology and therapeutics industry.

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.

Companies working in the same space as Stylus Medicine.

In the news

Stylus Medicine Launches to Develop Precision, In Vivo Genetic Medicines and Unlock the Full Potential of CAR-T Therapy - BioSpacebiospace.com · May 2025

Frequently asked questions

What does Stylus Medicine do?: Stylus Medicine develops in vivo genetic medicines using engineered recombinases, with initial focus on creating CAR-T therapies delivered via lipid nanoparticles for oncology, autoimmune, and genetic diseases.
Who founded Stylus Medicine?: Stylus Medicine was founded by Michael C. Bassik, Ph.D..
Who are Stylus Medicine's investors?: Stylus Medicine's investors include Brainstorm Ventures, CAL Innovation, California Innovation Fund, Khosla Ventures, Neva Sgr., RA Capital, Tachyon Ventures, AbbVie.